11-10-2018
ca-ssis / iStockphoto.com
The US Food and Drug Administration (FDA) has released guidance intended to advance the development of generic versions of complex medical drugs.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
US Food and Drug Administration, Scott Gottlieb, complex drugs, generic competition, Abbreviated New Drug Application, topical delivery systems
FDA unveils plans to boost innovation of medical devices
19-12-2018
FDA releases plan to boost biosimilars development
13-12-2018
FDA to focus on data in new ‘top strategic priority’
07-12-2018
FDA seeks revamp of medical devices approvals
27-11-2018
FDA improves generic approval rate under Trump: report
26-10-2018
FDA issues latest guidance to stop ‘gaming’ of system
03-10-2018
